Literature DB >> 19820014

Fetuin-A and change in body composition in older persons.

Joachim H Ix1, Christina L Wassel, Glenn M Chertow, Annemarie Koster, Karen C Johnson, Frances A Tylavsky, Jane A Cauley, Steven R Cummings, Tamara B Harris, Michael G Shlipak.   

Abstract

CONTEXT: Fetuin-A inhibits the insulin receptor in vitro. Higher serum fetuin-A concentrations are associated with type 2 diabetes longitudinally and greater adiposity in cross-sectional analyses. Whether higher fetuin-A concentrations are associated with accumulation of adiposity over time is unknown.
OBJECTIVE: To determine the association of fetuin-A levels with changes in body composition over 5 yr. STUDY
DESIGN: Observational cohort study nested in the Health Aging and Body Composition Study. PREDICTOR: Serum fetuin-A levels. OUTCOMES: Visceral adipose tissue (VAT), abdominal sc adipose tissue, and thigh muscle area by computed tomography, and waist circumference and body mass index were measured at baseline and again after 5 yr. Percent change and extreme change (>1.5 sds) in each measure were calculated.
RESULTS: Over 5 yr, subjects lost body mass in each measure, including 6% decline in VAT. Yet each sd (0.42 g/liter) higher fetuin-A concentration was associated with a 5.5% increase in VAT over 5 yr (95% confidence interval 1.9-9.2%; P = 0.003) in models adjusted for age, sex, race, clinical site, diabetes, physical activity, triglycerides, kidney function, and the baseline VAT score. Similarly, higher fetuin-A concentrations were associated with extreme VAT gain (relative risk 1.70, 95% confidence interval 1.12-2.60, P = 0.01). Fetuin-A concentrations were not statistically significant associated with change in any other measures of body composition (P > 0.20).
CONCLUSIONS: Higher fetuin-A concentrations are associated with the accumulation of VAT in well-functioning, community-living older persons. The mechanisms linking fetuin-A, VAT, and insulin resistance remain to be determined.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19820014      PMCID: PMC2775641          DOI: 10.1210/jc.2009-0916

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

Review 1.  Use and abuse of HOMA modeling.

Authors:  Tara M Wallace; Jonathan C Levy; David R Matthews
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

2.  Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity.

Authors:  P Auberger; L Falquerho; J O Contreres; G Pages; G Le Cam; B Rossi; A Le Cam
Journal:  Cell       Date:  1989-08-25       Impact factor: 41.582

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Comparison of body composition in middle-aged and elderly males using computed tomography.

Authors:  G A Borkan; D E Hults; S G Gerzof; A H Robbins
Journal:  Am J Phys Anthropol       Date:  1985-03       Impact factor: 2.868

5.  Weight stability masks sarcopenia in elderly men and women.

Authors:  D Gallagher; E Ruts; M Visser; S Heshka; R N Baumgartner; J Wang; R N Pierson; F X Pi-Sunyer; S B Heymsfield
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-08       Impact factor: 4.310

Review 6.  Hypothalamic regulation of adiposity: the role of 11beta-hydroxysteroid dehydrogenase type 1.

Authors:  Z Hochberg; M Friedberg; L Yaniv; T Bader; D Tiosano
Journal:  Horm Metab Res       Date:  2004-06       Impact factor: 2.936

7.  Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene.

Authors:  Suresh T Mathews; Gurmant P Singh; Mollie Ranalletta; Vivian J Cintron; Xiaoling Qiang; Anton Scott Goustin; Kai-Lin Catherine Jen; Maureen J Charron; Willi Jahnen-Dechent; George Grunberger
Journal:  Diabetes       Date:  2002-08       Impact factor: 9.461

8.  Prevalence and trends in obesity among US adults, 1999-2000.

Authors:  Katherine M Flegal; Margaret D Carroll; Cynthia L Ogden; Clifford L Johnson
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

9.  Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke.

Authors:  Cornelia Weikert; Norbert Stefan; Matthias B Schulze; Tobias Pischon; Klaus Berger; Hans-Georg Joost; Hans-Ulrich Häring; Heiner Boeing; Andreas Fritsche
Journal:  Circulation       Date:  2008-11-24       Impact factor: 29.690

10.  Adipocytokines attenuate the association between visceral adiposity and diabetes in older adults.

Authors:  Alka M Kanaya; Tamara Harris; Bret H Goodpaster; Fran Tylavsky; Steven R Cummings
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

View more
  18 in total

1.  Body fat distribution and inflammation among obese older adults with and without metabolic syndrome.

Authors:  Annemarie Koster; Sari Stenholm; Dawn E Alley; Lauren J Kim; Eleanor M Simonsick; Alka M Kanaya; Marjolein Visser; Denise K Houston; Barbara J Nicklas; Frances A Tylavsky; Suzanne Satterfield; Bret H Goodpaster; Luigi Ferrucci; Tamara B Harris
Journal:  Obesity (Silver Spring)       Date:  2010-04-15       Impact factor: 5.002

Review 2.  Fetuin-A: a novel link between obesity and related complications.

Authors:  J F Trepanowski; J Mey; K A Varady
Journal:  Int J Obes (Lond)       Date:  2014-12-03       Impact factor: 5.095

3.  Association of fetuin-a with incident diabetes mellitus in community-living older adults: the cardiovascular health study.

Authors:  Joachim H Ix; Mary L Biggs; Kenneth J Mukamal; Jorge R Kizer; Susan J Zieman; David S Siscovick; Dariush Mozzaffarian; Majken K Jensen; Lauren Nelson; Neil Ruderman; Luc Djousse
Journal:  Circulation       Date:  2012-04-17       Impact factor: 29.690

Review 4.  Metabolic Factors Determining the Susceptibility to Weight Gain: Current Evidence.

Authors:  Tim Hollstein; Paolo Piaggi
Journal:  Curr Obes Rep       Date:  2020-06

5.  Circulating alanine transaminase (ALT) and γ-glutamyl transferase (GGT), but not fetuin-A, are associated with metabolic risk factors, at baseline and at two-year follow-up: the prospective Cyprus Metabolism Study.

Authors:  Xiaowen Liu; Ole-Petter R Hamnvik; John P Chamberland; Michael Petrou; Huizhi Gong; Costas A Christophi; David C Christiani; Stefanos N Kales; Christos S Mantzoros
Journal:  Metabolism       Date:  2014-03-15       Impact factor: 8.694

6.  AMP-activated Protein Kinase (AMPK): Does This Master Regulator of Cellular Energy State Distinguish Insulin Sensitive from Insulin Resistant Obesity?

Authors:  X Julia Xu; Rudy J Valentine; Neil B Ruderman
Journal:  Curr Obes Rep       Date:  2014-06-01

7.  Serum fetuin A and chemerin levels correlate with hepatic steatosis and regional adiposity in maintenance hemodialysis patients.

Authors:  Hung-Yuan Chen; Chien-Chu Lin; Yen-Lin Chiu; Shih-Ping Hsu; Mei-Fen Pai; Ju-Yeh Yang; Yu-Sen Peng
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

8.  Relationship between serum levels of fetuin-A with apo-A1, apo-B100, body composition and insulin resistance in patients with type 2 diabetes.

Authors:  Farzad Shidfar; Mitra Zarrati; Mohamad Ebrahim Khamseh; Neda Haghighat; Ali Rostami; Hamid Zolfaghari
Journal:  Med J Islam Repub Iran       Date:  2014-09-20

9.  Fetuin-A is linked to improved glucose tolerance after short-term exercise training in nonalcoholic fatty liver disease.

Authors:  Steven K Malin; Anny Mulya; Ciaran E Fealy; Jacob M Haus; Mangesh R Pagadala; Amanda R Scelsi; Hazel Huang; Chris A Flask; Arthur J McCullough; John P Kirwan
Journal:  J Appl Physiol (1985)       Date:  2013-08-08

10.  Predicting total, abdominal, visceral and hepatic adiposity with circulating biomarkers in Caucasian and Japanese American women.

Authors:  Unhee Lim; Stephen D Turner; Adrian A Franke; Robert V Cooney; Lynne R Wilkens; Thomas Ernst; Cheryl L Albright; Rachel Novotny; Linda Chang; Laurence N Kolonel; Suzanne P Murphy; Loïc Le Marchand
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.